Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Report this comment to a moderator

Please fill in the form below if you think a comment is unsuitable. Please indicate which comment is of concern and why. Your comments will be sent to our moderator for review.

Report comment to moderator

MandatoryRequired fields.

Headline

We designed a new way of tapering antidepressants, but why won't the health authorities recognise its value?

Comment

This article highlights the paper-trail that is needed before a therapy/device can be formally approved within modern practice, despite the therapy/device making intuitive sense and having some data to back it up: https://www.tandfonline.com/doi/full/10.1080/17522439.2018.1469163. The solution? More studies, I'm afraid.

Posted date

13 OCT 2020

Posted time

12:21

Mandatory
Mandatory
Mandatory
Mandatory

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.